Quantitative Profiling of Human Renal UDP-glucuronosyltransferases and Glucuronidation Activity: A Comparison of Normal and Tumoral Kidney Tissues

Renal metabolism by UDP-glucuronosyltransferase (UGT) enzymes is central to the clearance of many drugs. However, significant discrepancies about the relative abundance and activity of individual UGT enzymes in the normal kidney prevail among reports, whereas glucuronidation in tumoral kidney has not been examined. In this study, we performed an extensive profiling of glucuronidation metabolism in normal (n = 12) and tumor (n = 14) kidneys using targeted mass spectrometry quantification of human UGTs. We then correlated UGT protein concentrations with mRNA levels assessed by quantitative polymerase chain reaction and with conjugation activity for the major renal UGTs. Beyond the wide interindividual variability in expression levels observed among kidney samples, UGT1A9, UGT2B7, and UGT1A6 are the most abundant renal UGTs in both normal and tumoral tissues based on protein quantification. In normal kidney tissues, only UGT1A9 protein levels correlated with mRNA levels, whereas UGT1A6, UGT1A9, and UGT2B7 quantification correlated significantly with their mRNA levels in tumor kidneys. Data support that posttranscriptional regulation of UGT2B7 and UGT1A6 expression is modulating glucuronidation in the kidney. Importantly, our study reveals a significant decreased glucuronidation capacity of neoplastic kidneys versus normal kidneys that is paralleled by drastically reduced UGT1A9 and UGT2B7 mRNA and protein expression. UGT2B7 activity is the most repressed in tumors relative to normal tissues, with a 96-fold decrease in zidovudine metabolism, whereas propofol and sorafenib glucuronidation is decreased by 7.6- and 5.2-fold, respectively. Findings demonstrate that renal drug metabolism is predominantly mediated by UGT1A9 and UGT2B7 and is greatly reduced in kidney tumors.

[1]  M. Manns,et al.  Differential down-regulation of the UDP-glucuronosyltransferase 1A locus is an early event in human liver and biliary cancer. , 1997, Cancer research.

[2]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[3]  R. Dellinger,et al.  Anti-Cancer Drugs Elicit Re-Expression of UDP-Glucuronosyltransferases in Melanoma Cells , 2012, PloS one.

[4]  B. Burchell,et al.  The expression of UDP-glucuronosyltransferases of the UGT1 family in human liver and kidney and in response to drugs. , 1993, Biochemical pharmacology.

[5]  F. Oesch,et al.  Extrahepatic metabolism at the body's internal–external interfaces , 2014, Drug metabolism reviews.

[6]  C. Guillemette,et al.  Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia. , 2013, Blood.

[7]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[8]  Jian Shi,et al.  Significantly Decreased and More Variable Expression of Major CYPs and UGTs in Liver Microsomes Prepared from HBV-Positive Human Hepatocellular Carcinoma and Matched Pericarcinomatous Tissues Determined Using an Isotope Label-free UPLC-MS/MS Method , 2014, Pharmaceutical Research.

[9]  Michèle Rouleau,et al.  Pharmacogenomics of Human Uridine Diphospho‐Glucuronosyltransferases and Clinical Implications , 2014, Clinical pharmacology and therapeutics.

[10]  C. Guillemette,et al.  Circulating estrogens in endometrial cancer cases and their relationship with tissular expression of key estrogen biosynthesis and metabolic pathways. , 2010, The Journal of clinical endocrinology and metabolism.

[11]  C. Guillemette,et al.  Glucuronidation of the Antiretroviral Drug Efavirenz by UGT2B7 and an in Vitro Investigation of Drug-Drug Interaction with Zidovudine , 2009, Drug Metabolism and Disposition.

[12]  Hendrik Neubert,et al.  Targeted Precise Quantification of 12 Human Recombinant Uridine-Diphosphate Glucuronosyl Transferase 1A and 2B Isoforms Using Nano-Ultra-High-Performance Liquid Chromatography/Tandem Mass Spectrometry with Selected Reaction Monitoring , 2013, Drug Metabolism and Disposition.

[13]  K. Knights,et al.  Renal drug metabolism in humans: the potential for drug–endobiotic interactions involving cytochrome P450 (CYP) and UDP‐glucuronosyltransferase (UGT) , 2013, British journal of clinical pharmacology.

[14]  Armando Santoro,et al.  Sorafenib: a review of its use in advanced hepatocellular carcinoma. , 2009, Drugs.

[15]  B. Leber,et al.  The sonic hedgehog factor Gli1 imparts drug resistance through inducible glucuronidation , 2014, Nature.

[16]  V. Zagonel,et al.  Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma , 2011, Open access journal of urology.

[17]  Shuji Ohno,et al.  Determination of mRNA Expression of Human UDP-Glucuronosyltransferases and Application for Localization in Various Human Tissues by Real-Time Reverse Transcriptase-Polymerase Chain Reaction , 2009, Drug Metabolism and Disposition.

[18]  Akio Kawamura,et al.  Protein quantification of UDP-glucuronosyltransferases 1A1 and 2B7 in human liver microsomes by LC-MS/MS and correlation with glucuronidation activities , 2012, Xenobiotica; the fate of foreign compounds in biological systems.

[19]  R. Fujiwara,et al.  Expression of UGT1A and UGT2B mRNA in Human Normal Tissues and Various Cell Lines , 2008, Drug Metabolism and Disposition.

[20]  B. Burchell,et al.  Drug glucuronidation by human renal UDP-glucuronosyltransferases. , 1998, Biochemical pharmacology.

[21]  M. W. Anders.  Metabolism of drugs by the kidney. , 1980, Kidney international.

[22]  M. Nagata,et al.  Optimized Methods for Targeted Peptide-Based Quantification of Human Uridine 5′-Diphosphate-Glucuronosyltransferases in Biological Specimens Using Liquid Chromatography–Tandem Mass Spectrometry , 2014, Drug Metabolism and Disposition.

[23]  C. Guillemette,et al.  Immunohistochemical expression of conjugating UGT1A‐derived isoforms in normal and tumoral drug‐metabolizing tissues in humans , 2011, The Journal of pathology.

[24]  K. Knights,et al.  Renal UDP-glucuronosyltransferases and the glucuronidation of xenobiotics and endogenous mediators , 2010, Drug metabolism reviews.

[25]  A. Starlard-Davenport,et al.  Novel identification of UDP-glucuronosyltransferase 1A10 as an estrogen-regulated target gene , 2008, Steroids.

[26]  Hendrik Neubert,et al.  Targeted quantitative proteomics for the analysis of 14 UGT1As and -2Bs in human liver using NanoUPLC-MS/MS with selected reaction monitoring. , 2013, Journal of proteome research.

[27]  Fernand Labrie,et al.  Specificity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyltransferases expressed in endometrium. , 2004, The Journal of clinical endocrinology and metabolism.

[28]  Takashi Baba,et al.  Quantification of human uridine-diphosphate glucuronosyl transferase 1A isoforms in liver, intestine, and kidney using nanobore liquid chromatography-tandem mass spectrometry. , 2012, Analytical chemistry.

[29]  Xinxin Ding,et al.  Quantitative distribution of mRNAs encoding the 19 human UDP-glucuronosyltransferase enzymes in 26 adult and 3 fetal tissues , 2012, Xenobiotica; the fate of foreign compounds in biological systems.

[30]  L. Ekström,et al.  Expression of UGT2B7 is driven by two mutually exclusive promoters and alternative splicing in human tissues: changes from prenatal life to adulthood and in kidney cancer , 2013, Pharmacogenetics and genomics.

[31]  C. Guillemette,et al.  Deferiprone Glucuronidation by Human Tissues and Recombinant UDP Glucuronosyltransferase 1A6: An in Vitro Investigation of Genetic and Splice Variants , 2009, Drug Metabolism and Disposition.

[32]  Yannick Duguay,et al.  Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone. , 2006, Cancer research.

[33]  R. Tukey,et al.  Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes , 2001, British journal of pharmacology.

[34]  E. Guo,et al.  Sorafenib Metabolism Is Significantly Altered in the Liver Tumor Tissue of Hepatocellular Carcinoma Patient , 2014, PloS one.

[35]  K. Knights,et al.  Human Renal Cortical and Medullary UDP-Glucuronosyltransferases (UGTs): Immunohistochemical Localization of UGT2B7 and UGT1A Enzymes and Kinetic Characterization of S-Naproxen Glucuronidation , 2007, Journal of Pharmacology and Experimental Therapeutics.

[36]  X. Chu,et al.  Metabolism and Renal Elimination of Gaboxadol in Humans: Role of UDP-Glucuronosyltransferases and Transporters , 2009, Pharmaceutical Research.